The drugmaker sees a “significant opportunity” to charge more for the weighty shot once it gets to the opposite side of the COVID-19 pandemic, one top chief says.

Pfizer set the current prices for the vaccine it created with its German partner, BioNTech, in view of the requirement for governments to get doses and get the virus leveled out, as per chief financial officer Frank D’Amelio.

For example, Pfizer is charging the US government $19.50 per dose — well underneath the $150 or $175 per dose it regularly pulls in for a vaccine, D’Amelio said on the company’s February earnings call.

In any case, “typical economic situations will begin to kick in” as the global pandemic movements into an endemic, D’Amelio said a week ago.

He proposed that those less-dire conditions could play for Pfizer’s potential benefit offered that its chance is 95% successful, the most noteworthy rate among the three vaccines presently cleared for use in the US.

“Components like adequacy, supporter capacity, clinical utility will fundamentally turn out to be vital, and we see that as, in all honesty, a significant opportunity for our vaccine from an interest viewpoint, from a valuing viewpoint, given the clinical profile of our vaccine,” D’Amelio said Thursday during the Barclays Global Healthcare Conference.

Yet, Pfizer said it expects governments will be the essential purchasers of its vaccine as the pandemic delays into 2022, during which time it hopes to keep prices low.

“We perceive the dire requirement for individuals everywhere on the world to get this vaccine and have as needs be set the cost of our vaccine for the pandemic time frame to support wide access, as opposed to utilizing conventional worth based estimating systems,” Pfizer representative Faith Salamon told The media in an email.

The Manhattan-based pharma giant as of now hopes to round up about $15 billion in deals this year from the two-dose COVID vaccine with an overall revenue of in excess of 20% of the shot’s absolute incomes.

Those benefits could get considerably bigger once Pfizer escapes the “pandemic-valuing climate,” D’Amelio told investors a month ago.

“Clearly, we will get more on value,” he said on Pfizer’s earnings call. “Also, obviously more the more volume we put through our factories, the lower unit cost will turn into.”

Pfizer additionally believes it’s “getting progressively likely” that individuals will require a yearly supporter shot to avert the COVID-19 variations that have arisen around the globe.

Pfizer has dispatched an investigation of a third vaccine dose to address the variations.

“We don’t consider this to be an onetime occasion, however we consider this to be something that will proceed for the foreseeable future,” D’Amelio said.

Pfizer shares moved about 0.9 percent to $ 35.72 as of 2:16 p.m.